The Pharma Data

APRIL 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. In the U.S.

Therapies 52

Therapies Disease Research Laboratories Treatment 52

Conversations in Drug Development Trends

JANUARY 24, 2024

Why Partnering with Genetic Counselors May Benefit Your Clinical Program The American College of Medical Genetics (ACMG) has issued a statement that geneticists should be involved in the development of genetic therapies. Enrolling adequate populations will be required to advance these programs.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Drug Target Review

APRIL 9, 2024

Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 64

RNA Cell Biology Clinical Development DNA 64

Vial

MARCH 1, 2024

billion in 2023 attributable to its laboratory products and biopharma services segment (53.8% By type of service, clinical research services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

JUNE 7, 2023

Consider the potential for drug interactions prior to and during PREVYMIS therapy; review concomitant medications during PREVYMIS therapy; and monitor for adverse reactions associated with PREVYMIS and concomitant medications. See additional Selected Safety Information below. Source link: [link]

FDA Approval 40

FDA Approval FDA Disease Research Laboratories 40

PPD

OCTOBER 24, 2024

Coordinated efforts are needed to combat this disease and improve the clinical status of persons with HBV infection. Currently there is no cure for hepatitis B, however there are several drugs in clinical development to improve the lives and clinical outcomes for persons with chronic HBV infection, including functional cure strategies.

Vaccine 52

Vaccine Virus Treatment Disease 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. Additionally, the capital will be used to further expand the existing laboratory capacities.

Therapies 52

Therapies International Disease Treatment 52

The Pharma Data

JUNE 2, 2023

Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low. 0.45]) and overall survival (OS) (HR=0.30 [95% CI, 0.15-0.59])

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. Hunt, a graduate research fellow in Jewett’s laboratory, is the paper’s co-first author.

Treatment 52

Treatment Virus Laboratories Engineering 52

The Pharma Data

AUGUST 31, 2021

today announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. Source link: [link].

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

JANUARY 21, 2021

Precigen is focused on next-generation gene and cell therapy using precision technology. The compound was developed in the laboratory of Richard Childs, chief of the Laboratory of Transplantation Immunotherapy with the National Heart, Lung, and Blood Institute (NHLBI). Precigen – Germantown, Md.-based It filed for a U.S.

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

NOVEMBER 9, 2020

These data also support the potential first-line use of LENVIMA plus everolimus, which is already approved in advanced RCC following prior antiangiogenic therapy,” said Dr. Takashi Owa, Vice President, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. Source link.

Research Laboratories 52

Research Laboratories Laboratories Treatment Therapies 52

The Pharma Data

JUNE 25, 2021

Merck is continuing to study KEYTRUDA, in combination or as monotherapy, as well as other investigational products across multiple settings and stages of RCC including adjuvant and advanced or metastatic disease through our broad clinical development program, which includes over 20 clinical studies and more than 4,000 patients.

Disease 52

Disease Therapies Treatment Medical Schools 52

PPD

MARCH 13, 2024

Within cell therapy clinical trials, apheresis collections contribute to the specific constituents of the given therapy. Whether this is via an allogeneic (healthy donors) or autologous (patient) approach, the material collected is then manufactured and returned to patients for infusion therapy.

Clinical Development 98

Clinical Development Clinical Trials Therapies Trials 98

The Pharma Data

JUNE 7, 2023

Patients who experience metastases at distant sites typically have worse survival outcomes and a poor prognosis, thus these results showing a reduction in the risk of distant recurrence underscore the potential of neoantigen therapy,” said Kyle Holen, M.D., Moderna’s Senior Vice President and Head of Development, Therapeutics and Oncology.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

PPD

NOVEMBER 14, 2023

In this complex environment, functional service partnership (FSP) models have become a solution of choice for pharmaceutical and biotech companies navigating the challenges of clinical development. Here’s how we do it. Recruitment and talent management are critical to FSP performance.

Clinical Research 52

Clinical Research Clinical Development International Engineering 52

Precision for Medicine

JUNE 26, 2023

Unraveling the complexity of manufacturing next-gen biologics is critical to the shared mission of accelerating patient access to new therapies,” said Chad Clark, President of Precision for Medicine. This convergence is driving faster clinical development and approval. For more information, visit projectfarma.com.

Science 40

Science Small Molecule Clinical Research Engineering 40

Precision for Medicine

MAY 24, 2023

“When choosing the right CRO partner, clinical innovators cannot make decisions based on assumptions of our capabilities because there is far too much at stake—significant financial investment, jobs for their people, and most importantly, the lives of patients that may view these therapies as a last hope for their future.

Clinical Trials 40

Clinical Trials Clinical Research Science Trials 40

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

The Pharma Data

NOVEMBER 8, 2020

HK) (“Pharmaron”), a fully integrated contract research and manufacturing organization offering laboratory, CMC and clinical development services for the life science industry, announced today that it has acquired 100% of the equity of Absorption Systems for up to US$137.5 Limited (Stock Code: 300759.SZ/3759.HK) million in cash.

Clinical Pharmacology 40

Clinical Pharmacology Laboratories Science Pharmaceuticals 40

The Pharma Data

OCTOBER 1, 2021

Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies. Data on the efficacy of deucravacitinib, no matter prior psoriasis treatment (Presentation FC03.06), were featured as an public speaking today from 2:30 – 3:30 p.m.

Disease 52

Disease Laboratories Clinical Pharmacology Treatment 52

The Pharma Data

JANUARY 19, 2021

The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is based in Suzhou and Shanghai, China.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

SEPTEMBER 28, 2021

Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Importantly, this treatment regimen are often utilized in combination with different chemotherapy agents.

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

JANUARY 21, 2021

Prior to joining Labcorp, she held multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. Abbott Laboratories and TAP Pharmaceuticals. a company previously known as miRagen Therapeutics.

Laboratories 52

Laboratories Pharmaceuticals Engineering Clinical Development 52

The Pharma Data

JANUARY 24, 2021

In a series of laboratory experiments, StemVacs administration was demonstrated to induce regression of GL261 glioma, CT-26 colorectal cancer, and Lewis Lung Carcinoma tumors grown in mice. OCEANSIDE, Calif., 25, 2021 /PRNewswire/ — Therapeutic Solutions International, Inc., (OTC ir@tsoimail.com.

International 52

International Laboratories Therapies Treatment 52

The Pharma Data

MARCH 16, 2021

While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders. “We Our mission is to create breakthrough therapies that change lives.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

MAY 31, 2022

The FDA grants priority review to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. who are unable to control their disease with systemic therapy and are most in need of a treatment option. There are approximately 75,000 people in the U.S.

FDA 52

FDA Disease Trials FDA Approval 52

Agency IQ

DECEMBER 1, 2023

Completed development of the EUDAMED Market Surveillance module Q4 2023 Designation of E.U. Reference Laboratories Proposal for five laboratories to receive E.U. Reference Laboratory designation Q4 2023 Critical medicines list [E.U.] Title Call for Evidence Closes Comments Close Planned Adoption Draft E.U.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

The Pharma Data

APRIL 4, 2022

FDA granted Breakthrough Therapy designation to Dupixent for the treatment of patients aged 12 years and older with EoE. Priority review is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. In September 2020, the U.S.

FDA 52

FDA Treatment Disease FDA Approval 52

The Pharma Data

JANUARY 20, 2021

Dr. John Teerlink – Professor of Medicine, University of California, San Francisco and Director of Heart Failure and the Echocardiographic Laboratory at the San Francisco Veterans Affairs Center. Wells is the author or co-author of over 400 published articles. About Cardiol Therapeutics. Cardiol Therapeutics Inc. (

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Clynes developed several novel therapeutic approaches in cancer and autoimmunity, including DC targeting for cancer vaccines and Syk and JAK mediated inhibition of DCs and T cells in autoimmunity therapy.

Virus 52

Virus Engineering Clinical Development International 52

The Pharma Data

NOVEMBER 22, 2020

The drug is a once-daily oral precision therapy designed for highly potent and selective targeting of oncogenic RET alterations. In addition to RET-altered NSCLC, it is being developed for RET-altered thyroid cancer and other solid tumors. The FDA approved it under the brand name Gavreto on September 4.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

NOVEMBER 20, 2020

Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Many Progeria patients have received continuous Zokinvy therapy for more than 10 years. PALO ALTO, Calif., 20, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Clinical Trials Disease 52

The Pharma Data

APRIL 28, 2023

We strongly believe in the results of the PROpel trial, which demonstrated a clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.” indication, patients are selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. In the U.S., For that U.S.

FDA 40

FDA FDA Approval Trials Treatment 40

The Pharma Data

APRIL 11, 2021

Monitor blood pressure after 1 week, at least monthly thereafter, and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Laboratory abnormalities (all grades; Grade 3-4) ?20% Retevmo was approved based on the Phase 1/2 LIBRETTO-001 trial’s endpoints of ORR and DoR.

Research 52

Research Therapies Treatment Trials 52